Oxford Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Oxford Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$23K	Sell	125 -5,160	-98%	-$1.3M	﹤0.01%	180
2019 Q4	$1.53M	Buy	5,285 +1,395	+36%	+$387K	0.04%	589
2019 Q3	$1.06M	Sell	3,890 -1,717	-31%	-$665K	0.03%	916
2019 Q2	$2.11M	Buy	5,607 +2,201	+65%	+$657K	0.05%	619
2019 Q1	$913K	Sell	3,406 -1,871	-35%	-$444K	0.02%	968
2018 Q4	$1.12M	Buy	5,277 +3,436	+187%	+$1.07M	0.03%	807
2018 Q3	$831K	Sell	1,841 -2,890	-61%	-$1.26M	0.02%	1095
2018 Q2	$1.93M	Buy	4,731 +764	+19%	+$364K	0.04%	689
2018 Q1	$2.16M	Buy	+3,967	New	+$2.46M	0.05%	530

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Oxford Asset Management's PVLA Position: Q1 2020 in Review

Oxford Asset Management reduced its Palvella Therapeutics (PVLA) stake by 98% in Q1 2020, selling an estimated $1.3M and leaving 125 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #180.

Oxford Asset Management first reported a position in PVLA in Q1 2018 and has held it in 9 quarters since. The position peaked at $2.16M in Q1 2018. 95 funds tracked by Wall St. Rank hold PVLA as of Q1 2020.

Oxford Asset Management held 125 shares of Palvella Therapeutics worth $23K as of Q1 2020.
Oxford Asset Management sold 5,160 Palvella Therapeutics shares in Q1 2020, an estimated $1.3M.
Palvella Therapeutics made up ﹤0.01% of Oxford Asset Management's portfolio in Q1 2020, its #180 holding.
Oxford Asset Management first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 9 quarters since.
Oxford Asset Management's Palvella Therapeutics position peaked at $2.16M in Q1 2018.
95 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.